{
    "xml": "<topic id=\"PHP5470\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/hydroxycarbamide\" basename=\"hydroxycarbamide\" title=\"HYDROXYCARBAMIDE\">\n<title>HYDROXYCARBAMIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1052\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/hydroxycarbamide\">Hydroxycarbamide</xref>\n</p>\n<data name=\"vtmid\">56602009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_934934062\" title=\"Ribonucleotide reductase inhibitors\">Ribonucleotide reductase inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">\r\n<b>Hydroxyurea</b>\r\n</p>\r\n</body>\n<topic id=\"PHP67192\" outputclass=\"indicationsAndDose\" rev=\"1.22\" parent=\"/drugs/hydroxycarbamide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of chronic myeloid leukaemia</p>\n<p outputclass=\"therapeuticIndication\">Treatment of cancer of the cervix in conjuction with radiotherapy</p>\n<p outputclass=\"therapeuticIndication\">Polycythaemia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8211;30&#8239;mg/kg daily, alternatively 80&#8239;mg/kg every 3&#8239;days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Sickle-cell disease &#8212;consult with a specialist centre</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 15&#8239;mg/kg daily, increased in steps of 2.5&#8211;5&#8239;mg/kg daily, dose to be increased every 12 weeks according to response; usual dose 15&#8211;30&#8239;mg/kg daily; maximum 35&#8239;mg/kg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67274\" outputclass=\"importantSafetyInformation\" rev=\"1.8\" parent=\"/drugs/hydroxycarbamide\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p>\n<p>Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67307\" outputclass=\"cautions\" rev=\"1.15\" parent=\"/drugs/hydroxycarbamide\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Leg ulcers (review treatment if cutaneous vasculitic ulcerations develop)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67168\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/hydroxycarbamide\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (hydroxycarbamide).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67049\" outputclass=\"sideEffects\" rev=\"1.33\" parent=\"/drugs/hydroxycarbamide\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Headache</ph>; <ph outputclass=\"sideEffect\">myelosuppression</ph>; <ph outputclass=\"sideEffect\">skin reactions</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Amenorrhoea (in sickle-cell disease)</ph>; <ph outputclass=\"sideEffect\">fever (in sickle-cell disease)</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bleeding (in sickle-cell disease)</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">hypomagnesaemia (in sickle-cell disease)</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">reduced sperm count and activity</ph>; <ph outputclass=\"sideEffect\">skin cancers (particularly in elderly patients)</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67292\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/hydroxycarbamide\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given before cytotoxic therapy begins; manufacturer advises effective contraception before and during treatment.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">When used for <ph outputclass=\"indication\">Chronic myeloid leaukaemia</ph> or <ph outputclass=\"indication\">Cancer of the cervix</ph>\n</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67140\" outputclass=\"pregnancy\" parent=\"/drugs/hydroxycarbamide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenic in <i>animal</i> studies).</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67312\" outputclass=\"breastFeeding\" parent=\"/drugs/hydroxycarbamide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67228\" outputclass=\"hepaticImpairment\" parent=\"/drugs/hydroxycarbamide\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in mild to moderate impairment.</p>\n<p>Avoid in severe impairment, unless used for malignant conditions.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67087\" outputclass=\"renalImpairment\" parent=\"/drugs/hydroxycarbamide\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>In sickle-cell disease, reduce initial dose by 50% if eGFR less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>In sickle-cell disease, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Use with caution in malignant disease.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66915\" outputclass=\"monitoringRequirements\" parent=\"/drugs/hydroxycarbamide\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor renal and hepatic function before and during treatment.</p>\n<p>Monitor full blood count before treatment, and repeatedly throughout use; in sickle-cell disease monitor every 2 weeks for the first 2 months and then every 2 months thereafter (or every 2 weeks if on maximum dose).</p>\n</sectiondiv>\n<sectiondiv>\n<p>Patients receiving long-term therapy for malignant disease should be monitored for secondary malignancies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67127\" outputclass=\"patientAndCarerAdvice\" rev=\"1.21\" parent=\"/drugs/hydroxycarbamide\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients receiving long-term therapy with hydroxycarbamide should be advised to protect skin from sun exposure.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5470-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/hydroxycarbamide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension, capsule</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75800\" title=\"Tablet\" namespace=\"/drugs/hydroxycarbamide/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75779\" title=\"Capsule\" namespace=\"/drugs/hydroxycarbamide/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78093\" namespace=\"/treatment-summaries/sickle-cell-disease\" title=\"Sickle-cell disease\" count=\"2\" rel=\"backlink\">Sickle-cell disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1052\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/hydroxycarbamide\" title=\"Hydroxycarbamide\" count=\"1\" rel=\"link\">Hydroxycarbamide</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75800\" namespace=\"/drugs/hydroxycarbamide/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75779\" namespace=\"/drugs/hydroxycarbamide/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP5470",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/hydroxycarbamide",
    "basename": "hydroxycarbamide",
    "title": "HYDROXYCARBAMIDE",
    "interactants": [
        {
            "id": "bnf_int_1052",
            "label": "Hydroxycarbamide"
        }
    ],
    "vtmid": "56602009",
    "drugClassification": [
        "Ribonucleotide reductase inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Hydroxyurea"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of chronic myeloid leukaemia",
                        "html": "Treatment of chronic myeloid leukaemia"
                    },
                    {
                        "textContent": "Treatment of cancer of the cervix in conjuction with radiotherapy",
                        "html": "Treatment of cancer of the cervix in conjuction with radiotherapy"
                    },
                    {
                        "textContent": "Polycythaemia",
                        "html": "Polycythaemia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "20&#8211;30 mg/kg daily, alternatively 80 mg/kg every 3 days.",
                        "html": "<p>20&#8211;30&#8239;mg/kg daily, alternatively 80&#8239;mg/kg every 3&#8239;days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Sickle-cell disease &#8212;consult with a specialist centre",
                        "html": "Sickle-cell disease &#8212;consult with a specialist centre"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 15 mg/kg daily, increased in steps of 2.5&#8211;5 mg/kg daily, dose to be increased every 12 weeks according to response; usual dose 15&#8211;30 mg/kg daily; maximum 35 mg/kg per day.",
                        "html": "<p>Initially 15&#8239;mg/kg daily, increased in steps of 2.5&#8211;5&#8239;mg/kg daily, dose to be increased every 12 weeks according to response; usual dose 15&#8211;30&#8239;mg/kg daily; maximum 35&#8239;mg/kg per day.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.\n\nStandards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Leg ulcers (review treatment if cutaneous vasculitic ulcerations develop)",
                "html": "Leg ulcers (review treatment if cutaneous vasculitic ulcerations develop)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (hydroxycarbamide).",
                "html": "<p>Appendix 1 (hydroxycarbamide).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Headache",
                        "html": "Headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "myelosuppression",
                        "html": "myelosuppression",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "skin reactions",
                        "html": "skin reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Amenorrhoea (in sickle-cell disease)",
                        "html": "Amenorrhoea (in sickle-cell disease)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "fever (in sickle-cell disease)",
                        "html": "fever (in sickle-cell disease)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bleeding (in sickle-cell disease)",
                        "html": "bleeding (in sickle-cell disease)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypomagnesaemia (in sickle-cell disease)",
                        "html": "hypomagnesaemia (in sickle-cell disease)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "reduced sperm count and activity",
                        "html": "reduced sperm count and activity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "skin cancers (particularly in elderly patients)",
                        "html": "skin cancers (particularly in elderly patients)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given before cytotoxic therapy begins; manufacturer advises effective contraception before and during treatment.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given before cytotoxic therapy begins; manufacturer advises effective contraception before and during treatment.</p>"
            },
            {
                "type": "generalInformation",
                "specificity": {
                    "textContent": "When used for Chronic myeloid leaukaemia or Cancer of the cervix",
                    "html": "When used for <ph outputclass=\"indication\">Chronic myeloid leaukaemia</ph> or <ph outputclass=\"indication\">Cancer of the cervix</ph>",
                    "indications": [
                        "Chronic myeloid leaukaemia",
                        "Cancer of the cervix"
                    ]
                },
                "textContent": "Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenic in animal studies).\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.",
                "html": "<p>Avoid (teratogenic in <i>animal</i> studies).</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in mild to moderate impairment.\n\nAvoid in severe impairment, unless used for malignant conditions.",
                "html": "<p>Manufacturer advises caution in mild to moderate impairment.</p><p>Avoid in severe impairment, unless used for malignant conditions.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "In sickle-cell disease, reduce initial dose by 50% if eGFR less than 60 mL/minute/1.73 m2.",
                "html": "<p>In sickle-cell disease, reduce initial dose by 50% if eGFR less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "In sickle-cell disease, avoid if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>In sickle-cell disease, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            },
            {
                "type": "generalInformation",
                "textContent": "Use with caution in malignant disease.",
                "html": "<p>Use with caution in malignant disease.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor renal and hepatic function before and during treatment.\n\nMonitor full blood count before treatment, and repeatedly throughout use; in sickle-cell disease monitor every 2 weeks for the first 2 months and then every 2 months thereafter (or every 2 weeks if on maximum dose).",
                "html": "<p>Monitor renal and hepatic function before and during treatment.</p><p>Monitor full blood count before treatment, and repeatedly throughout use; in sickle-cell disease monitor every 2 weeks for the first 2 months and then every 2 months thereafter (or every 2 weeks if on maximum dose).</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Patients receiving long-term therapy for malignant disease should be monitored for secondary malignancies.",
                "html": "<p>Patients receiving long-term therapy for malignant disease should be monitored for secondary malignancies.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients receiving long-term therapy with hydroxycarbamide should be advised to protect skin from sun exposure.",
                "html": "<p>Patients receiving long-term therapy with hydroxycarbamide should be advised to protect skin from sun exposure.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension",
                "capsule"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75800",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75779",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78093",
                "label": "Sickle-cell disease",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1052",
                "label": "Hydroxycarbamide",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75800",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75779",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}